Molnupiravir To Reach 105 LMICs Through MPP Agreement
Almost 30 Generics Manufacturers Will Be Producing Low-Cost Versions Of The Antiviral
Almost 30 generics firms based across 11 countries have signed up to agreements with the Medicines Patent Pool to facilitate the supply of oral COVID-19 treatment molnupiravir to 105 low- and-middle-income countries. The move follows an agreement signed in October by the MPP with Merck.
You may also be interested in...
After the Medicines Patent Pool secured a licensing deal with ViiV Healthcare for long-acting injectable cabotegravir for HIV pre-exposure prophylaxis, prospective generic sub-licensees have until 4 September to submit expressions of interest.
Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.
An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.